BJDX Bluejay Diagnostics, Inc.

BEARISH Impact: 5/10 PRESS-RELEASE
Horizon weeks Filed Jun 2, 2026 Processed 3d 3h ago Wire GlobeNewswire
Press release: offering
Latest settled — T+1d ⚠ clustered
BJDX ▲ +3.92% at T+1d
SHORT call ✗ call lost -3.92% · α vs SPY -4.61% · entry $4.34 → $4.51
Next anchor: T+5d in 4d
Currently $4.90 · -12.90% from $4.34 entry (call sign-flipped)
Entry anchored
Jun 2, 12:18 PM ET
via Databento tick
T+1d
+3.92%
call -3.92% · α -4.61%
$4.51
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Bluejay Diagnostics announced a private placement raising $8.5 million upfront (up to $23.6 million with warrant exercise), priced at $2.325 per share. The offering is highly dilutive given the company's $2 million market cap, but the proceeds extend cash runway into Q1 2027, supporting FDA submission efforts.

Key Financial Metrics

Deal Value
$8.5M

Actionable Insight

The offering provides a cash lifeline for FDA submission but imposes massive dilution. Monitor for Nasdaq listing compliance and warrant exercise activity. Further dilution risk remains if warrants are exercised, adding overhang.

Key Facts

  • Private placement of 3,655,917 shares plus series G and H warrants at $2.325 per unit
  • Gross proceeds of $8.5 million upfront, up to $15.1 million additional from warrant exercise
  • Net proceeds expected to extend cash runway into Q1 2027; if warrants fully exercised, beyond FDA approval and first year of commercialization
  • Offering priced at-the-market under Nasdaq rules; dilution is substantial relative to current market cap of $2M
  • H.C. Wainwright & Co. acted as exclusive placement agent
  • Proceeds to fund FDA approval activities (clinical studies), R&D, and working capital

Financial Impact

Immediate $8.5M gross proceeds; potential total $23.6M if all warrants exercised. Dilution of roughly 80%+ based on pre-offering share count implied by market cap.

cashdilutionshare count

Risk Factors

  • Extreme dilution to existing shareholders
  • FDA approval uncertainty could lead to further capital needs
  • Warrant overhang if exercised could pressure stock price

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305486
6 reports for BJDX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BJDX — sortable, filterable
Type Now
Jun 2, 2026
3d ago
Press Release
BEARISH ★ 5/10
$4.34 $4.51▼ −3.92%▼ −4.61%$4.90 (−12.90%)
Jun 2, 2026
3d ago
PRESS-RELEASE / 8-K
NEUTRAL ★ 4/10
$4.34 $4.51▲ +3.92%▲ +4.61%$4.90 (+12.90%)
May 18, 2026
17d ago
Insider Cluster
BULLISH ★ 7/10
awaiting T+1
May 7, 2026
28d ago
8-K
NEUTRAL ★ 3/10
$1.72 $1.76▲ +2.33%▲ +2.09%$4.90 (+184.88%)
May 7, 2026
28d ago
Press Release
NEUTRAL ★ 2/10
$1.72 $1.76▲ +2.33%▲ +2.09%$4.90 (+184.88%)
Apr 7, 2026
8w ago
8-K
BULLISH ★ 6/10
$2.05 $2.05· 0.00%▼ −2.54%$4.90 (+139.02%)
Showing 6 of 6

US Market Status

Market Open — Closes in 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access